Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572585 | 0.89 | SLC6A9 (0.32) | SLC6A9 | |
| SCHEMBL30146794 | 0.89 | SLC6A9 (0.32) | SLC6A9 | |
| SCHEMBL9962599 | 0.88 | RAF1 (0.33) | RAF1BRAFPTK2MAPK10MAPK9 | |
| SCHEMBL9929600 | 0.88 | PTK2 (0.35) | RAF1BRAFPTK2MAPK10MAPK9 | |
| SCHEMBL29664057 | 0.88 | PTK2 (0.35) | RAF1BRAFPTK2MAPK10MAPK9 | |
| SCHEMBL1963554 | 0.86 | — | — | |
| SCHEMBL1964070 | 0.86 | — | — | |
| SCHEMBL25605286 | 0.84 | RAF1 (0.33) | RAF1BRAFPTK2ULK1ALDH1A1 | |
| SCHEMBL21585210 | 0.84 | SLC6A9 (0.31) | SLC6A9 | |
| SCHEMBL25716498 | 0.82 | TNIK (0.35) | RAF1BRAFULK1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045971-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2652553-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2652553-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8518546-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2012082383-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20110143141-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110143141-A1 | Photochromic compounds and compositions | CCNA1, CRY1, CCNT1 | RAF1 3521/4885BRAF 2643/4885PTK2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.